What is the price target for LMRI stock?
12 analysts have analysed LMRI and the average price target is 23.12 USD. This implies a price increase of 190.09% is expected in the next year compared to the current price of 7.97.
LUMEXA IMAGING HOLDINGS INC (LMRI) Forecast, Price Target & Analyst Ratings
NASDAQ:LMRI • US5502491062
Current stock price
7.97 USD
+0.18 (+2.31%)
At close:
7.97 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LUMEXA IMAGING HOLDINGS INC (LMRI).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- $0.17
- Revenue Estimate
- 259.75M
Price Target Details & History
Consensus Price Target and Range
Mean target
$23.12
Upside
+ 190.09%
From current price of $7.97 to mean target of $23.12, Based on 12 analyst forecasts
Low
$22.22
Median
$23.46
High
$24.15
Price Target Revisions
1 Month
0.30%
3 Months
N/A
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for LMRI. The average price target is 23.12 USD. This implies a price increase of 190.09% is expected in the next year compared to the current price of 7.97.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.00%
LMRI was analyzed by 12 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about LMRI.
In the previous month the buy percentage consensus was at a similar level.
LMRI was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-09 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2026-01-05 | Leerink Partners | Initiate | Outperform |
| 2026-01-05 | William Blair | Initiate | Outperform |
| 2026-01-05 | Deutsche Bank | Initiate | Buy |
| 2026-01-05 | Barclays | Initiate | Overweight |
| 2026-01-05 | Wells Fargo | Initiate | Overweight |
| 2026-01-05 | Raymond James | Initiate | Outperform |
| 2026-01-05 | Jefferies | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- $0.17
- Revenue Estimate
- 259.75M
- Revenue Q2Q
- N/A
- EPS Q2Q
- N/A
- Number of Analysts
- 9
Next Earnings Revisions
Revenue (1 Month)
-0.24%
Revenue (3 Months)
N/A
EPS (1 Month)
-2.85%
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2026 - 2027
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 935.925M | 948.869M 1.38% | 1.023B 7.82% | 1.087B 6.25% | 1.148B 5.61% | |
| EBITDA YoY % growth | 43.802M | 25.902M -40.87% | 67.112M 159.10% | 242.88M 261.90% | 261.44M 7.64% | |
| EBIT YoY % growth | -12.828M | -16.262M -26.77% | 26.733M 264.39% | 155.6M 482.05% | 186.24M 19.69% | |
| Operating Margin | -1.37% | -1.71% | 2.61% | 14.31% | 16.22% | |
| EPS YoY % growth | N/A | N/A | N/A | 0.80 5,508.14% | 1.05 30.64% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.17 | 0.19 | 0.21 | 0.23 135.28% | 0.22 31.51% | 0.25 31.43% | 0.26 23.92% | 0.27 16.81% |
| Revenue Q2Q % growth | 259.75M | 268.04M | 275.64M -63.51% | 279.84M -72.65% | 273.8M 5.41% | 283.29M 5.69% | 290.84M 5.51% | 299.69M 7.09% |
| EBITDA Q2Q % growth | 55.792M | 58.864M | 62.073M -0.18% | 65.79M 99.91% | 61.235M 9.76% | 64.504M 9.58% | 66.905M 7.78% | 69.05M 4.96% |
| EBIT Q2Q % growth | 37.315M | 39.681M | 42.307M 23.69% | 46.927M 728.21% | 47.727M 27.90% | 50.565M 27.43% | 52.287M 23.59% | 53.609M 14.24% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
LUMEXA IMAGING HOLDINGS INC / LMRI Forecast FAQ
What are the consensus estimates for LMRI stock next earnings?
The consensus EPS estimate for the next earnings of LUMEXA IMAGING HOLDINGS INC (LMRI) is 0.17 USD and the consensus revenue estimate is 259.75M USD.
What is the consensus rating for LUMEXA IMAGING HOLDINGS INC (LMRI) stock?
The consensus rating for LUMEXA IMAGING HOLDINGS INC (LMRI) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.